Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

C. Massard, J. Mateo, Y. Loriot, C. Pezaro, L. Albiges, N. Mehra, A. Varga, D. Bianchini, C. J. Ryan, D. P. Petrylak, G. Attard, L. Shen, K. Fizazi, J. de Bono

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone'. Together they form a unique fingerprint.

Medicine & Life Sciences